Product Information
MATZIM LA 300 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $1.7799 per EA under NDC 52544069319. Its NADAC has been published 583 times since Nov 28, 2013.
Strength
300 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
52544069319
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
DILTIAZEM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA077686On Market Since
3/28/2011
Pharmacological Classes
Price Statistics
The NADAC for MATZIM LA 300 MG TABLET has been published 583 times since Nov 28, 2013, and over the history we have for it it has declined 46.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.7799 per EA |
|---|---|
| All-time high | $3.3997 (Jun 15, 2016) |
| All-time low | $1.2965 (Jan 21, 2026) |
| 52-week high | $2.9349 |
| 52-week low | $1.2965 |
| Median price | $3.1678 |
| Average price | $2.9817 |
| Largest weekly change | +33.9% (Oct 23, 2024) |
| Weeks tracked | 583 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 6 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 6 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 90% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of MATZIM LA 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MATZIM LA 300 MG TABLET, manufactured by Actavis Pharma, Inc., is $1.7799 per EA (NDC 52544069319), effective Jun 24, 2026.
How has the price of MATZIM LA 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for MATZIM LA 300 MG TABLET has declined 46.3%. It has been tracked across 583 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MATZIM LA 300 MG TABLET?
Since Nov 28, 2013, the NADAC for MATZIM LA 300 MG TABLET has ranged from a low of $1.2965 (Jan 21, 2026) to a high of $3.3997 (Jun 15, 2016), with a median of $3.1678 per EA.
Are there cheaper alternatives to MATZIM LA 300 MG TABLET?
Yes. 6 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, DILTIAZEM 24HR ER 300 MG CAP, is $0.1729 per EA — about 90% below MATZIM LA 300 MG TABLET.
Who manufactures MATZIM LA 300 MG TABLET?
MATZIM LA 300 MG TABLET (NDC 52544069319) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification